Cargando…
Immunogenicity Associated with Botulinum Toxin Treatment
Botulinum toxin (BoNT) has been used for the treatment of a variety of neurologic, medical and cosmetic conditions. Two serotypes, type A (BoNT-A) and type B (BoNT-B), are currently in clinical use. While considered safe and effective, their use has been rarely complicated by the development of anti...
Autores principales: | Bellows, Steven, Jankovic, Joseph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784164/ https://www.ncbi.nlm.nih.gov/pubmed/31454941 http://dx.doi.org/10.3390/toxins11090491 |
Ejemplares similares
-
Reply to Comment on Re-Visiting Immunogenicity Associated with Botulinum Toxin Treatment. Toxins 2019, 11, 491
por: Bellows, Steven, et al.
Publicado: (2020) -
Immunogenicity of botulinum toxins
por: Naumann, Markus, et al.
Publicado: (2012) -
Immunogenicity of botulinum toxin
por: Wee, Syeo Young, et al.
Publicado: (2022) -
Botulinum Toxin in Movement Disorders: An Update
por: Anandan, Charenya, et al.
Publicado: (2021) -
Botulinum Toxin for the Treatment of Hand Tremor
por: Niemann, Nicki, et al.
Publicado: (2018)